AYBINTIO is a biosimilar medicine designed to mimic the therapeutic effects of its reference product, Avastin (bevacizumab), which is a monoclonal antibody. It works by inhibiting the growth of blood vessels that supply tumors, thereby preventing the tumor from growing and spreading. AYBINTIO is used in the treatment of various types of cancers, including colorectal, lung, glioblastoma, kidney, and cervical cancers among others. It operates by targeting and inhibiting the vascular endothelial growth factor (VEGF), a key substance that promotes angiogenesis (the formation of new blood vessels). By blocking VEGF, AYBINTIO effectively starves tumors of the necessary nutrients and oxygen needed for their growth, contributing to the inhibition of tumor progression. This biosimilar offers a more cost-effective alternative while maintaining the efficacy and safety profile similar to its reference product.